Waltham, MA-based Syndax Pharmaceuticals named former AstraZeneca chief medical officer Briggs Morrison its new CEO, and Michael Metzger, onetime Regado Biosciences president and CEO, its new president. Morrison and and Metzger are replacing former leader Arlene Morris—whose name was conspicuously absent from the news release. FierceBiotech first reported news of Morrison’s departure from AstraZeneca last week. Read more here for the immuno-oncology focused strategy that Syndax—which flirted with an IPO last year under Morris—intends to pursue.
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
